Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT04012658
Recruiting Observational

A Registered Cohort Study on Wilson's Disease

NCT04012658 · tracked via the Priya Life Science China tracker
Sponsor
Wan-Jin Chen
Phase
Observational
Started
2019-07-01
Last updated
2019-09-23

Condition(s) studied

Wilson's Disease

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

The aim of this study is to determine the clinical spectrum and natural progression of Wilson's Disease in a prospective multicenter natural history study, to assess the clinical, genetic, epigenetic features and biomarkers of patients with Wilson's Disease to optimize clinical management.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with the genetic diagnosis of Wilson's Disease * Asymptomatic Wilson's Disease carriers * Relatives of Wilson's Disease patients or carriers * Unrelated healthy controls * Participants or Parent(s)/legal guardian(s) willing and able to complete the informed consent process Exclusion Criteria: \* Participants are unable to comply with study procedures and visit schedule

Primary outcome measure(s)

  • The change of Unified Wilson's Disease Rating Scale (UWDRS) — Up to 30years
    Disease severity will be assessed by application of the Unified Wilson's Disease Rating Scale (UWDRS), a clinical rating scale consists of three subscales. Higher UWDRS total scores indicate more severe disease.

Trial sites (1)

FacilityCityRegionStatus
First Affiliated Hospital of Fujian Medical University Fuzhou China Recruiting

More Wan-Jin Chen trials in China

A Registered Cohort Study on Spastic Paraplegia Recruiting
A Registered Cohort Study on Brain Calcification Recruiting
Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke Active, not recruiting
A Registered Cohort Study on SMA Recruiting

Other trials for the same condition

Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. Recruiting
Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's Disease Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04012658 on ClinicalTrials.gov ↗ ← All trials in China